Aptamer Group PLC Aptamer Group signs two substantial new contracts (6087N)
January 24 2023 - 2:00AM
UK Regulatory
TIDMAPTA
RNS Number : 6087N
Aptamer Group PLC
24 January 2023
24 January 2023
Aptamer Group plc
("Aptamer", the "Company" or the "Group")
Aptamer Group signs two substantial new contracts
- Contracts worth over GBP500,000 with the potential for
downstream milestone and royalty/ licensing payments
Aptamer Group plc (AIM: APTA), the developer of novel Optimer(R)
binders to enable innovation in the life sciences industry,
announces the recent signing of two new fee-for-service contracts
initially worth over GBP500,000, subject to the successful
progression of Optimer development, with the potential for
downstream milestone and royalty/licensing payments. These latest
contracts are in addition to GBP1.0m of recognised revenue in H1,
as well as the additional GBP1.0m in signed orders, announced in
Aptamer's recent trading update.
The first contract is with BaseCure Therapeutics, a pre-clinical
stage biotech company dedicated to the discovery and development of
innovative siRNA-based medicines. Aptamer is working with BaseCure
Therapeutics to identify cell targeting Optimer binders that might
be developed as potential delivery vehicles for siRNA uptake into
target cells and tissues. The ability to achieve Optimer-directed
targeted delivery would offer exciting new therapeutic
opportunities of siRNA-mediated gene knockdown in these target
cells and tissues.
The second contract is with a developer of custom enzymes based
in Asia. Aptamer will develop Optimer binders for incorporation
into a biosensor to allow convenient monitoring of the ingredients
in the company's manufacturing processes. As these ingredients are
typically small molecule targets, antibodies often struggle to
develop the required levels of selectivity to these targets.
Dr Arron Tolley, Chief Executive Officer, commented: "Signing
these two substantial deals is a solid start to the second half for
Aptamer Group. The diverse nature of these partnerships
demonstrates the broad applicability of the Optimer platform across
the life science industry, from supporting improved manufacturing
methods to developing new drugs and the increased need for novel
antibody alternatives within the life science market. I look
forward to updating the market regarding progress for these deals
and new partnerships in due course."
- ENDS -
For further information, please contact:
Aptamer Group plc
Dr Arron Tolley +44 (0) 1904 217 404
SPARK Advisory Partners Limited - Nominated Adviser
Andrew Emmott / Adam Dawes +44 (0) 20 3368 3550
Liberum Capital Limited - Broker
Richard Lindley / Ben Cryer / Cara Murphy +44 (0) 20 3100
2000
Consilium Strategic Communications
Matthew Neal / Chris Welsh / Lucy Featherstone +44 (0) 20 3709 5700
aptamergroup@consilium-comms.com
About Aptamer Group plc
Aptamer Group develops custom affinity binders through its
proprietary Optimer(R) platform to enable new approaches in
therapeutics, diagnostics and research applications. The Company
strives to deliver transformational solutions that meet the needs
of life science researchers and developers through the use of its
proprietary Optimer platform.
Optimer binders are oligonucleotide affinity ligands that can
function as an antibody alternative. The global antibody market is
currently worth over $145.0 billion. Optimer binders are engineered
to address many of the issues found with alternative affinity
molecules, such as antibodies, and offer new, innovative solutions
to bioprocessing, diagnostic and pharmaceutical scientists.
Aptamer Group has successfully delivered projects for global
pharma companies, diagnostic development companies, and research
institutes covering a range of targets and applications with the
objective of establishing royalty-bearing licenses. Through the
unique Optimer technology and processes, scientists and
collaborators are enabled to make faster, more informed decisions
that support discovery and development across the Life
Sciences.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCBIGDBBXDDGXX
(END) Dow Jones Newswires
January 24, 2023 02:00 ET (07:00 GMT)
Aptamer (LSE:APTA)
Historical Stock Chart
From Apr 2024 to May 2024
Aptamer (LSE:APTA)
Historical Stock Chart
From May 2023 to May 2024